CD4 and dengue disease: Although the protection of rMV-TDV against DENV-2 infection evidenced by reduced viremia and no inflammatory cytokine increase was encouraging, the immunodominant DENV-3 CD4+ T-cell responses induced by the tetravalent dengue vaccine attracted more attention.